Menu
Back to Journals » Breast Cancer: Targets and Therapy
Breast Cancer: Targets and Therapy
ISSN: 1179-1314
Editor-in-Chief: Professor Pranela Rameshwar
Breast Cancer: Targets and Therapy is an international, peer reviewed, open access journal focusing on breast cancer, basic and translational research, clinical trials and treatment. The latter includes outcome studies that incorporate preventative and integrated treatment strategies for enhanced survival, and quality of life for cancer patients.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).
Articles:
- View all (500)
- Volume 16, 2024 (29)
- Volume 15, 2023 (79)
- Volume 14, 2022 (41)
- Volume 13, 2021 (58)
- Volume 12, 2020 (27)
- Volume 11, 2019 (32)
- Volume 10, 2018 (24)
- Volume 9, 2017 (64)
- Volume 8, 2016 (26)
- Volume 7, 2015 (36)
- Volume 6, 2014 (20)
- Volume 5, 2013 (13)
- Volume 4, 2012 (22)
- Volume 3, 2011 (16)
- Volume 2, 2010 (9)
- Volume 1, 2009 (4)
Latest articles:
- 5 records -
Metabolomics in Radiotherapy-Induced Early Adverse Skin Reactions of Breast Cancer Patients
McMahon AN, Lee E, Takita C, Reis IM, Wright JL, Hu JJ
Breast Cancer: Targets and Therapy 2024, 16:369-377
Published Date: 16 July 2024
Breast Cancer Adjuvant Radiotherapy in Up-Front to Chemotherapy: Is There a Worthwhile Benefit? A Preliminary Report
Lazzari G, Benevento I, Montagna A, D'Andrea B, De Marco G, Castaldo G, Bianculli A, Tucciariello R, Metallo V, Solazzo AP
Breast Cancer: Targets and Therapy 2024, 16:359-367
Published Date: 15 July 2024
Research Progress on Ferroptosis and Nanotechnology-Based Treatment in Triple-Negative Breast Cancer
Zhang J, Zhang S, Liu M, Yang Z, Huang R
Breast Cancer: Targets and Therapy 2024, 16:347-358
Published Date: 15 July 2024
Role of AURKB Inhibition in Reducing Proliferation and Enhancing Effects of Radiotherapy in Triple-Negative Breast Cancer
Pellizzari S, Athwal H, Bonvissuto AC, Parsyan A
Breast Cancer: Targets and Therapy 2024, 16:341-346
Published Date: 9 July 2024
The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker
Buyukbayram ME, Hannarici Z, Duzkopru Y, Turhan A, Caglar AA, Coban Esdur P, Bilici M, Tekin SB, Yazılıtaş D
Breast Cancer: Targets and Therapy 2024, 16:329-339
Published Date: 3 July 2024